Skip to main content
. 2017 Sep 8;18(9):1931. doi: 10.3390/ijms18091931

Table 1.

Relationship between the TRIM44 immunoreactivity and clinicopathological parameters in 129 breast cancer patients. ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; IR, immunoreactivity; SEM, standard error of the mean.

TRIM44 Status p-Value
Weak IR (n = 62) Strong IR (n = 67)
Age (±SEM) 55.6 ± 1.4 52.2 ± 1.3 0.044
 ≤50 years old 22 34 0.081
 >50 years old 40 33
Stage 0.933
 I 31 33
 II, III 31 34
Pathological tumor size 0.476
 ≤20 mm 36 43
 >20 mm 26 24
Lymph node status 0.131
 Negative 44 39
 Positive 18 28
ER status 0.305
 Negative 8 5
 Positive 54 62
PgR status 0.201
 Negative 18 13
 Positive 44 54
HER2 status 0.353
 Negative 51 59
 Positive 11 8
Nuclear grade 0.033
 1 42 33
 2, 3 20 34